Overview

PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

Status:
Completed

Trial end date:
2017-12-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to ask whether treating non-diabetic chronic kidney disease (CKD) patients with GFR 8-20mL/min/1.73m2 by darbepoetin Alfa targeting Hb between 11.0 and 13.0g/dL preserves renal function better than targeting Hb between 9.0 and11.0g/dL. The investigators also ask whether the higher Hb targeting 11 to 13g/dL will not cause higher adverse events regarding cardiovascular diseases compared with lower Hb targeting 9 to 11g/dL.

Phase:

Phase 3

Details

Lead Sponsor:

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Translational Research Informatics Center, Kobe, Hyogo, Japan

Collaborator:

Showa University School of Medicine

Treatments:

Darbepoetin alfa